These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 32317316)

  • 1. Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?
    Xie W; Wang Y; Zhang Z
    Ann Rheum Dis; 2021 Jan; 80(1):e6. PubMed ID: 32317316
    [No Abstract]   [Full Text] [Related]  

  • 2. Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?' by Xie
    Gamboa-Alonso CM; Figueroa-Parra G; Galarza-Delgado DA
    Ann Rheum Dis; 2021 Jan; 80(1):e7. PubMed ID: 32571868
    [No Abstract]   [Full Text] [Related]  

  • 3. Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.
    Monti S; Montecucco C
    Ann Rheum Dis; 2020 Jun; 79(6):e62. PubMed ID: 32327429
    [No Abstract]   [Full Text] [Related]  

  • 4. Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy.
    Macías J; González-Moreno P; Sánchez-García E; Morillo-Verdugo R; Pérez-Venegas JJ; Pinilla A; Macho M; Martínez M; González-Serna A; Corma A; Real LM; Pineda JA
    PLoS One; 2021; 16(4):e0249036. PubMed ID: 33831011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
    Sanchez-Piedra C; Diaz-Torne C; Manero J; Pego-Reigosa JM; Rúa-Figueroa Í; Gonzalez-Gay MA; Gomez-Reino J; Alvaro-Gracia JM;
    Ann Rheum Dis; 2020 Jul; 79(7):988-990. PubMed ID: 32503857
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of SARS-CoV-2 infection in patients with rheumatic conditions on hydroxychloroquine monotherapy vs. patients without rheumatic conditions: A retrospective, propensity-matched cohort study.
    Gentry CA; Thind SK; Williams RJ; Hendrickson SC; Kurdgelashvili G; Humphrey MB
    Am J Med Sci; 2023 Jan; 365(1):19-25. PubMed ID: 36103912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 infection among patients with systemic autoimmune diseases.
    Emmi G; Bettiol A; Mattioli I; Silvestri E; Di Scala G; Urban ML; Vaglio A; Prisco D
    Autoimmun Rev; 2020 Jul; 19(7):102575. PubMed ID: 32376395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.
    Sarzi-Puttini P; Marotto D; Antivalle M; Salaffi F; Atzeni F; Maconi G; Monteleone G; Rizzardini G; Antinori S; Galli M; Ardizzone S
    Autoimmun Rev; 2020 Jul; 19(7):102574. PubMed ID: 32376399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory Action to Protect Access to Hydroxychloroquine for Approved Rheumatic Indications During COVID-19 in New Zealand.
    Duffy E; Arroll N; Beasley R; Hills T
    Arthritis Rheumatol; 2021 May; 73(5):896-897. PubMed ID: 33410583
    [No Abstract]   [Full Text] [Related]  

  • 10. Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic.
    Lauper K; Bijlsma JWJ; Burmester GR
    Ann Rheum Dis; 2021 Jan; 80(1):26-30. PubMed ID: 33055081
    [No Abstract]   [Full Text] [Related]  

  • 11. Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline.
    Bugatti S; De Stefano L; Bobbio-Pallavicini F; Montecucco C
    RMD Open; 2020 Oct; 6(3):. PubMed ID: 33087414
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to: 'Implications of SARS-CoV-2 infection for patients with rheumatic disease' by Lin
    Mathian A; Amoura Z
    Ann Rheum Dis; 2022 Aug; 81(8):e153. PubMed ID: 32895236
    [No Abstract]   [Full Text] [Related]  

  • 13. Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic.
    Scuccimarri R; Sutton E; Fitzcharles MA
    J Rheumatol; 2020 Jun; 47(6):783-786. PubMed ID: 32241801
    [No Abstract]   [Full Text] [Related]  

  • 14. [Current guidance of the German Society of Rheumatology for the care of patients with rheumatic diseases during the SARS-CoV-2/Covid 19 pandemic].
    Schulze-Koops H; Holle J; Moosig F; Specker C; Aries P; Burmester G; Fiehn C; Hoyer B; Krause A; Leipe J; Lorenz HM; Schneider M; Sewerin P; Voormann A; Wager U; Krüger K; Iking-Konert C;
    Z Rheumatol; 2020 May; 79(4):385-388. PubMed ID: 32342184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
    Nina PB; Dash AP
    Indian J Public Health; 2020 Jun; 64(Supplement):S125-S127. PubMed ID: 32496241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
    Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
    RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to 'To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic' by Parperis.
    Spinelli FR; Ceccarelli F; Di Franco M; Conti F
    Ann Rheum Dis; 2021 Jan; 80(1):e9. PubMed ID: 32366521
    [No Abstract]   [Full Text] [Related]  

  • 18. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.
    Mikuls TR; Johnson SR; Fraenkel L; Arasaratnam RJ; Baden LR; Bermas BL; Chatham W; Cohen S; Costenbader K; Gravallese EM; Kalil AC; Weinblatt ME; Winthrop K; Mudano AS; Turner A; Saag KG
    Arthritis Rheumatol; 2020 Aug; 72(8):1241-1251. PubMed ID: 32349183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.
    Malviya A
    Indian Heart J; 2020; 72(2):131-132. PubMed ID: 32534688
    [No Abstract]   [Full Text] [Related]  

  • 20. Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic.
    Peschken CA
    J Rheumatol; 2020 Jun; 47(6):787-790. PubMed ID: 32269064
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.